Atossa receives FDA Rare Pediatric and Orphan Drug designations for (Z)-endoxifen in DMD; pauses MBC

ATOSSA THERAPEUTICS, INC.

FDA Rare Pediatric Disease and Orphan Drug designations granted for (Z)-endoxifen in Duchenne Muscular Dystrophy (Dec 2025/Jan 2026).
Paused investment in metastatic breast cancer (MBC) to prioritize other oncology and rare disease programs.
Cash and equivalents >$40M as of early 2026, supporting >1 year of working capital.
Reverse stock split effective Feb 2, 2026 to regain Nasdaq listing compliance.
I-SPY 2 combination therapy enrollment near complete; preliminary data expected H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.